1887

oa CSIR Science Scope - Using biologics to transform the drug marketplace : pharmaceutical and chemical sectors

Volume 6, Issue 2
  • ISSN :

 

Abstract

The CSIR is currently building capacity for large-scale recombinant production of biopharmaceuticals. At present, there are a number of such products at various stages in the development pipeline, including therapeutic peptides such as Exenatide (diabetes treatment), Enfurvitide and Griffithsin (HIV inhibitors) as well as anti-rabies monoclonal antibodies (mAbs).

Loading full text...

Full text loading...

Loading

Article metrics loading...

/content/csir_sci/6/2/EJC121217
2012-04-01
2017-08-24

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error